Using Open-Source Software to Drive Reliability and Security in Lab & Life Sciences

 

Open-Source software’s flexibility through its distribution with the source code gives programmers the power to modify and distribute with its original rights. That versatility allows many technological innovations within the Health and Life Science space. Intel partners with Health and Life Science organizations on a wide range of solutions, and open-source is critical to bringing new advancements to life. 

Health and Life Science at the Edge’s Morgan Andersen welcomed Intel Product Manager Amy Gilliam and Director of Security Communications Christopher Robinson for a discussion on open-source, everything from what it is, what the culture is like, and managing the quality of the code.

Gilliam says the culture around open source has grown to become a collaborative environment that’s enhanced over the years. Open exchange, de-centralized coding collaboration and peer review are all norms that move open source in a positive direction. “Peer review is a huge part of the open-source development process, in which developers submit code, it gets reviewed by multiple team members and project members before it gets integrated into the main code base by the maintainer,” Gilliam adds. 

From Robinson’s perspective, open source thrives because of the collaboration community. “I’ve been doing security in upstream open source for just under a decade, and I get to work with people from all around the world. We used to have a concept frequently talked about; it was called meritocracy; whereas you were contributing to these communities, people would put forth other ideas, and normally the best idea will win out. After much review and conversation, you’ll generally have better quality code because you’ve had all these different types of inputs.” 

So, how does security factor into open source when privacy is critical to a lot of work done in the health and life science world? Some essential regulations and rules govern the industry to protect human life. Gilliam says technology developers must familiarize themselves with these regulations and ensure the flexibility and capability to meet those compliance requirements now and in the future. 

“The FDA requires disclosures of software submission,” Gilliam said. “So, along with those disclosures of software, are usually calling out of risks and mitigations. Those can be cybersecurity risks, privacy risks, etc. We’re monitoring for that as we’re building software and these analytical tools that will help leverage and accelerate processes in the pharmaceutical industry.” 

Learn more about Open Source solutions by connecting with Amy Gilliam and Christopher Robinson on LinkedIn or visit Intel Health and Life Sciences. 

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Network and Edge Solutions Group.

Follow us on social media for the latest updates in B2B!

Image

Latest

patient
Rebecca Interview: When Peer-to-Peer Reviews Stop Being About the Patient
December 2, 2025

Behind the sterile labels of “inpatient” versus “observation” care is a messy reality: clinicians and insurers often enter peer-to-peer reviews without a shared rulebook, turning what should be a clinical dialogue into a box-checking exercise. The speaker’s frustration points to a broader problem in U.S. healthcare utilization management—decisions about coverage can feel pre-decided,…

Read More
physician advisor
Navigating Payer Denials: A Physician Advisor’s Perspective #2
December 2, 2025

A physician advisor recently described a case that should unsettle anyone who cares about fair, clinically grounded coverage decisions: a Medicaid patient arrived comatose from an overdose, was emergently intubated, developed aspiration pneumonia, and stayed through three midnights before leaving against medical advice. By any bedside standard, this is acute, unstable care—exactly what…

Read More
Inside ERISA Denials: Why Employers May Be the Real Decision-Makers Behind Your Insurance Card
December 2, 2025

Insurance denials aren’t new, but they’re hitting a breaking point right now. As prior authorizations surge and patients face longer delays for everything from imaging to specialty drugs, more providers are realizing that the “payer” on the card often isn’t the one truly holding the reins. A growing share of Americans are covered…

Read More
Laying Out the Landscape in Today’s Patient Monitoring
Laying Out the Landscape in Today’s Patient Monitoring
December 2, 2025

More and more hospital environments rely on continuous, high-quality data to support faster clinical decisions, but much of today’s patient monitoring still varies widely by unit, device, and workflow. This episode kicks off a five-part Health and Life Sciences at the Edge series exploring The Future of Patient Monitoring. Intel’s Kaeli Tully, Solutions Engineer…

Read More